MXCT vs STT · rev $38.6M vs P/E 17, $45.02B cap
MaxCyte Inc (MXCT) versus State Street Corp (STT) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
State Street Corp (STT) is a asset management company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
STT does not have a complete income-statement cache yet.
MXCT currently screens at market cap $124.3M. STT currently screens at market cap $45.02B and trailing P/E 16.5.
Not investment advice. Open the MXCT and STT stock pages for the full models.
Not investment advice.